Last reviewed · How we verify

Delgocitinib cream — Competitive Intelligence Brief

Delgocitinib cream (Delgocitinib cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor. Area: Dermatology / Immunology.

phase 3 JAK inhibitor JAK1, JAK2, JAK3, TYK2 Dermatology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Delgocitinib cream (Delgocitinib cream) — LEO Pharma. Delgocitinib is a JAK inhibitor that suppresses inflammatory cytokine signaling in immune cells to reduce skin inflammation and itching in atopic dermatitis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Delgocitinib cream TARGET Delgocitinib cream LEO Pharma phase 3 JAK inhibitor JAK1, JAK2, JAK3, TYK2
Janus Kinase Inhibitor Janus Kinase Inhibitor Peking Union Medical College Hospital marketed Janus Kinase Inhibitor JAK1, JAK2, JAK3, TYK2
Pf-07293893 pf-07293893 Pfizer marketed JAK inhibitor Janus kinase (JAK) pathway Not available
Xeljanz tofacitinib Pfizer marketed JAK inhibitor Janus kinase (JAK) enzymes 2012-01-01
Xeljanz Tofacitinib Citrate Pfizer marketed JAK inhibitor Janus kinase (JAK) enzymes 2012-01-01
Xeljanz Tofacitinib Citrate Pfizer marketed JAK inhibitor Janus kinase (JAK) enzymes 2012-01-01
CP-690,550 CP-690,550 Pfizer marketed JAK inhibitor JAK1, JAK3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

  1. Pfizer · 19 drugs in this class
  2. Aclaris Therapeutics, Inc. · 2 drugs in this class
  3. Beijing Friendship Hospital · 2 drugs in this class
  4. Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
  5. CAGE Bio Inc. · 1 drug in this class
  6. CTI BioPharma · 1 drug in this class
  7. Celgene · 1 drug in this class
  8. Fred Hutchinson Cancer Center · 1 drug in this class
  9. LEO Pharma · 1 drug in this class
  10. McMaster University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Delgocitinib cream — Competitive Intelligence Brief. https://druglandscape.com/ci/delgocitinib-cream. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: